Clinical and molecular consequences of exon 78 deletion in DMD gene by Traverso, Monica et al.
Journal of Human Genetics
https://doi.org/10.1038/s10038-018-0439-6
BRIEF COMMUNICATION
Clinical and molecular consequences of exon 78 deletion in DMD
gene
Monica Traverso1 ● Stefania Assereto2 ● Serena Baratto2 ● Michele Iacomino1 ● Marina Pedemonte2 ●
Maria Cristina Diana2 ● Marta Ferretti2 ● Paolo Broda2 ● Carlo Minetti1,2 ● Elisabetta Gazzerro2 ● Francesca Madia3 ●
Claudio Bruno2 ● Federico Zara3 ● Chiara Fiorillo1,2
Received: 5 October 2017 / Revised: 5 February 2018 / Accepted: 19 February 2018
© The Author(s) under exclusive licence to The Japan Society of Human Genetics 2018
Abstract
We present a 13-year-old patient with persistent increase of serum Creatine Kinase (CK) and myalgia after exertion. Skeletal
muscle biopsy showed marked reduction of dystrophin expression leading to genetic analysis of DMD gene by MLPA,
which detected a single deletion of exon 78. To the best of our knowledge, DMD exon 78 deletion has never been described
in literature and, according to prediction, it should lead to loss of reading frame in the dystrophin gene. To further assess the
actual effect of exon 78 deletion, we analysed cDNA from muscle mRNA. This analysis confirmed the absence of 32 bp of
exon 78. Exclusion of exon 78 changes the open reading frame of exon 79 and generate a downstream stop codon, producing
a dystrophin protein of 3703 amino acids instead of 3685 amino acids. Albeit loss of reading frame usually leads to protein
degradation and severe phenotype, in this case, we demonstrated that deletion of DMD exon 78 can be associated with a
functional protein able to bind DGC complex and a very mild phenotype. This study adds a novel deletion in DMD gene in
human and helps to define the compliance between maintaining/disrupting the reading frame and clinical form of the disease.
Introduction
Duchenne muscular dystrophy (DMD, OMIM #310200)
and its milder allelic variant and Becker muscular dystrophy
(BMD, OMIM #300376) are both caused by mutations in
the DMD gene located on Xp21. DMD represents the most
common genetic neuromuscular disease of childhood, with
an incidence of 1 in 3500 male live birth [1].
DMD is characterized by progressive muscle degenera-
tion, with overt onset of muscle weakness by age 7–8 years,
subsequent loss of mobility and premature death. The pro-
gression of BMD is slower and signs and symptoms appear
usually after 10 years of age. In many BMD patients,
mobility is preserved for a long time.
The DMD, one of the largest human gene, consists of 79
exons, encodes a 14-kb mRNA (NM_004006.2) [2–4] and
produces the dystrophin. Dystrophin is a sarcolemma-
associated protein, which binds cytoskeletal actin through
its N-terminal domain, and a complex of dystrophin-
associated proteins through its C-terminal domain [3].
Intragenic deletions and duplications account for over
two-thirds of the mutations leading to DMD and BMD and
the remainder may be due to point mutations [5, 6].
The major determinant of disease severity is whether the
mutation results in an mRNA that maintains an open
reading frame (ORF) allowing translation of a functional
amino- and carboxy-terminal [7].
In Duchenne patients, mutations induce a shift in the
reading frame leading to prematurely truncated, dysfunc-
tional dystrophin. In Becker patients, in-frame mutations
allow the synthesis of internally deleted, but largely func-
tional dystrophin [8].
In this study, we provide a clinical and histopathological
portrait of previously unreported DMD exon 78 deletion,
particularly focusing on genotype–phenotype correlations
and molecular effect of this mutation that appears to be
exception to the reading-frame rule.
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A 13-year-old boy came to our unit for persistent increase
of serum Creatine Kinase (CK), associated with myalgia
after exertion.
Born at term from healthy unrelated parents, the boy
displayed normal psychomotor development. Clinical his-
tory was unremarkable until age 12 years when he started
agonist boating with training six times a week. Motor per-
formance were excellent and alike his peers, however, he
started complaining of myalgia after exercise. For persis-
tence of the symptoms, routine lab exams were indicated by
general paediatrician at age 12 years and 5 months, which
revealed increased CK level (2465 U/L), whereas other
results were all normal. After a period of rest from exercise,
CK levels were measured again at 1 and 2 months later and
resulted still elevated (285 U/L and 633 U/L, respectively).
Being in good health, he resumed boating, but at age 12
years and 9 months, he was admitted in Emergency
Department for severe pain in chest and interscapular
region. Electrocardiogram documented unspecific alteration
of right bundle transmission. Cardiological examination
was clinically normal. Troponin was normal, however CK
was still elevated (751 U/L).
At age 13 years, he was admitted to our hospital. CK at
admission was 680 U/L. Height and weight were above
70th percentile. Intellectual functions were normal. Neuro-
logical examination revealed only mild hypotrophy
of shoulder girdle and pectoral muscles. Strength was
normal.
Skeletal muscle biopsy was performed at age 13 years
and 2 months from left quadriceps, after signing informed
consent. Routine histological and histochemical techniques,
including immunofluorescence study were performed.
Haemotoxylin and eosin staining showed slight fibre size
variation, absence of degeneration and necrosis, and mini-
mal increase of connective tissue. Immunofluorescence
study with specific antibodies for sarcolemmal dystrophin
(NCL-DYS1 against Rod domain DYS-ROD, NCL-DYS2
against C-terminal DYS-COOH, NCL-DYS3 against N-
terminal DYS-NH, Novocastra, UK) showed normal stain-
ing for DYS-NH and DYS-ROD, whereas expression of
DYS-COOH, corresponding to the last 17 amino acids, was
nearly absent. Other DGC-complex proteins, including
beta-dystroglycan (NCL-b-DG Novocastra, UK) and sar-
coglycans showed normal staining. Immunofluorescence for
utrophin (NCL-DRP2, Novocastra, UK), which is expected
increased in DMD patients, did not show an increased
expression of the protein (Fig. 1).
Genomic DNA was extracted from peripheral blood
leukocytes using standard protocol and DMD gene deletions
and duplications were tested by multiplex-ligation-depen-
dent-probe-amplification (MLPA) (SALSA P034 and
SALSA P035, MRC-Holland). MLPA analysis surprisingly
demonstrated a single deletion of exon 78 in hemizygous
(Fig. 2a). Segregation analysis showed that the deletion was
not present in the mother, however one older sister was
found heterozygous carrier, implying germinal mosaicism
in the mother. A 30-year-old brother was also tested for
diagnostic and prognostic purposes, but he resulted normal.
Fig. 1 Upper panel: frozen muscle tissue sections of the patient
immunolabelled with Novocastra antibodies against dystrophin N-
terminal (DYS-NH), dystrophin Rod domain (DYS-ROD) and dys-
trophin C-terminal (DYS-COOH) with control muscle section (CTRL)
in square box in upper corner. Final magnification, ×20. In lower
panel: frozen muscle tissue sections of the patient immunolabelled
with Novocastra antibodies against beta-dystroglycan and utrophin
(final magnification, ×20) and stained with standard H&E staining
(final magnification, ×10). Representative images are shown
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PCR amplification of exon 78 from genomic DNA,
with intronic primers 5′-tttttccctttctgatatctctgc-3′ and
3′-cctctccacttgcagctcat-5′, showed absence of the
expected amplificated fragment, confirming the deletion of
the exon 78.
To explore the actual effect of the DNA deletion on
mRNA, we performed cDNA direct sequencing for
exons 77–79 with ad hoc designed primers. Sequences of
this portion confirmed the total absence of the 32 bp,
corresponding to the 11 amino acids of exon 78 (Fig. 2b).
Exclusion of exon 78 from DMD transcript changes the
ORF of the last exon 79. The new ORF generates
a new downstream stop codon, producing a dystrophin
protein of 3703 amino acids instead of 3685 amino
acids. Bioinfomatic study in ExPASy 2.0 software con-
firmed the loss of the reading frame and creation of incor-
rect amino acid sequence in the very last part of the
dystrophin.
Fig. 2 a Multiplex-ligation-
dependent-probe-amplification
result showing the absence of
exon 78 (arrow) in proband, and
a reduction of the peak in the
sister (arrow head),
corresponding to the carrier
status. b cDNA sequencing for
exons 77–79 of DMD gene in
normal control and in proband.
Amino acid sequence is
indicated below the
electropherogram. Asterisk
correspond to stop codon in the
correct cDNA sequence. In
proband, exon 78 (orange bar) is
missing, and a new boundery
between exon 77 (yellow bar)
and exon 79 (light blue bar) is
formed. Exon 79 is 28 aa longer
due to the loss of the reading
frame and the shift of the stop
codon (stop loss). The new
amino acid sequence of exon 79
is shown in red. (colour figure
online)
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Discussion
In this study, we report on a BMD patient with very mild
clinical presentation, carrying a previously unreported
deletion of exon 78 in DMD gene.
According to prediction, this deletion should lead to a
loss of the reading frame with putative DMD phenotype.
Several authors have already delineate exceptions of this
reading-frame rule, accounting for up to 10% of cases [8, 9].
This patient adds a novel mutation to the list of mutations in
DMD gene that do not follow this rule. Furthermore, the
effect of specific mutations affecting the C-terminal domain
is matter of debate, as they give rise to both severe DMD or
unexpectedly mild BMD phenotype [10]. A possible
explanation for this clinical variability is the evasion of the
nonsense-mediated decay in selected cases [11]. Our case is
of particular interest because single-genomic deletion of
exon 78 associated to DMD or BMD phenotype has never
been object of study in human. Abnormal splicing of DMD
exon 78 has been described in dystrophic muscles of
patients affected by myotonic dystrophy type 1, as con-
sequence of the DMPK gene defect [12]. According to
authors, aberrant exon 78 deleted DMD compromises
muscle fibre maintenance and contributes to the progressive
dystrophic process. Conversely, histopathology study of our
patient suggests that exon 78 deletion only minimally
affects muscle fibres morphology and architecture (Fig. 1f).
We also demonstrated that deletion of exon 78 changes
the ORF of exon 79, resulting in a dystrophin protein of
3703 amino acids instead of 3685 amino acids, presumably
without significantly impairing its function. In fact, the
binding sites for beta-dystroglycan and other proteins of
DGC complex reside before exon 78, in particular, in
exons 63–70 for beta-dystroglycan. Accordingly, Immuno-
Fluorescence studies demonstrated that binding for beta-
dystroglycan is preserved. Thus, we hypothesize that loss of
DMD exon 78 does not interfere with formation of normal
dystrophin protein and functional DGC complex, whereas
the absent expression of C-terminal antibody is only due to
technical reason (binding antigen of this antibody in the last
17 aa).
Taken together, we believe these data are useful in
clinical practice and in deciphering the results of molecular
and histopathological investigations of dystrophinopathy
patients.
Compliance with ethical standards
Conflict of interest The authors declare that they have no conflict of
interest.
Ethical publication statement All authors confirm they have read the
position on issues involved in ethical publication and affirm that this
report is consistent with those guidelines.
References
1. Worton RG, Thompson MW. Genetics of Duchenne muscular
dystrophy. Annu Rev Genet. 1988;22:601–29.
2. Koenig M, Monaco AP, Kunkel LM. The complete sequence of
dystrophin predicts a rod-shaped cytoskeletal protein. Cell.
1988;53:219–28.
3. Ahn AH, Kunkel LM. The structural and functional diversity of
dystrophin. Nat Genet. 1993;3:283–91.
4. Freund AA, Scola RH, Arndt RC, Lorenzoni PJ, Kay CK, Wer-
neck LC. Duchenne and Becker muscular dystrophy: a molecular
and immunohistochemical approach. Arq Neuropsiquiatr.
2007;65:73–6.
5. Koenig M, Beggs AH, Moyer M, Scherpf S, Heindrich K, Bet-
tecken T, et al. The molecular basis for Duchenne versus Becker
muscular dystrophy: correlation of severity with type of deletion.
Am J Hum Genet. 1989;45:498–506.
6. Den Dunnen JT, Grootscholten PM, Bakker E, Blonden LA,
Ginjaar HB, Wapenaar MC, et al. Topography of the Duchenne
muscular dystrophy (DMD) gene: FIGE and cDNA analysis of
194 cases reveals 115 deletions and 13 duplications. Am J Hum
Genet. 1989;45:835–47.
7. Flanigan KM. Duchenne and Becker muscular dystrophies. Neu-
rol Clin. 2014;32:671–88.
8. Aartsma-Rus A, Van Deutekom JC, Fokkema IF, Van Ommen
GJ, Den Dunnen JT. Entries in the Leiden Duchenne muscular
dystrophy mutation database: an overview of mutation types and
paradoxical cases that confirm the reading-frame rule. Muscle
Nerve. 2006;34:135–44.
9. Aartsma-Rus A, GinJaar IB, Bushby K. The importance of genetic
diagnosis for Duchenne muscular dystrophy. J Med Genet.
2016;53:145–51.
10. Crawford GE, Faulkner JA, Crosbie RH, Campbell KP, Froehner
SC, Chamberlain JS. Assembly of the dystrophin-associated
protein complex does not require the dystrophin COOH-terminal
domain. J Cell Biol. 2000;150:1399–410.
11. Kerr TP, Sewry CA, Robb SA, Roberts RG. Long mutant dys-
trophins and variable phenotypes: evasion of nonsense-mediated
decay? Hum Genet. 2001;109:402–7.
12. Rau F, Lainé J, Ramanoudjame L, Ferry A, Arandel L, Delalande
O, et al. Abnormal splicing switch of DMD’s penultimate exon
compromises muscle fibre maintenance in myotonic dystrophy.
Nat Commun. 2015;6:7205.
M. Traverso et al.
